Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma

The treatment and evolution of B-cell non-Hodgkin lymphoma (B-NHL) has undergone important changes in the last years with the emergence of targeted therapies, such as monoclonal antibodies, small molecules, antibody-drug conjugates, and bispecific antibodies. Nevertheless, a significant portion of p...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Alvaro J. Alencar, Alexandre V. Hirayama, Diego V. Clé, Marco Aurélio Salvino, Guilherme Perini, Celso Arrais, Otávio Baiocchi, Leonardo Carvalho Palma, Iago Colturato, Jorge Vaz, Ricardo Chiattone, Marcos de Lima, Jayr Schmidt Filho, Samir Nabhan, Vanderson Rocha, Renato L. Guerino-Cunha, Carlos S. Chiattone
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Cellular therapy
CAR-T cells
Immunotherapy
Adoptive cellular therapy
Advanced cellular therapy
Non-Hodgkin lymphoma
Diseases of the blood and blood-forming organs
RC633-647.5
Acceso en línea:https://doaj.org/article/fb9f576e4fc64cbf847cfdf061ac8b7e
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/fb9f576e4fc64cbf847cfdf061ac8b7e

Ejemplares similares